Intravenous immunoglobulin application following immunoadsorption: Benefit or risk in patients with autoimmune diseases?

Rheumatology

Volumn 40, Issue 5, 2001, Pages 513-521

  Schmaldienst, S ^a   Mullner M ^a   Goldammer, A ^a   Spitzauer, S ^b   Banyai, S ^a   Horl W H ^a   Derfler, K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Autoantibody resynthesis; Autoimmune disease; Immunoadsorption; Infection; Intravenous immunoglobulins; Side effects

Indexed keywords

AUTOANTIBODY; ENDOBULIN PRO TIM; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADULT; ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; BACKACHE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG INFUSION; FEMALE; FLUSHING; HUMAN; HYPOTENSION; IMMUNOADSORPTION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RATE; LONG TERM CARE; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; URTICARIA; VERTIGO;

EID: 0034981525     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/40.5.513     Document Type: Article

References (61)

1. Klinische Immunoadsorption
2. Immunoadsorption in systemic connective tissue diseases and primary vasculitis
3. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus
4. Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis
5. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin
6. Characteristics of 73 patients, 1984-1993, treated by plasma exchange for Guillain-Barre syndrome
7. Therapeutic plasma exchange: An update from the Canadian Apheresis group
8. Plasmapheresis and immunoadsorption: Different techniques and their current role in medical therapy
9. Efficacy and safety of immunoglobulin apheresis
10. Elimination of acquired factor VIII antibodies by extracorporeal antibody-based immunoadsorption (Ig-Therasorb)
11. Rapid elimination of high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression
12. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy
13. Extracorporeal removal of anti-HLA antibodies in transplant candidates
14. Reduction of acquired high titer factor VIII antibodies by extracorporeal antibody-based immunoadsorption without additional immunosuppressive therapy
15. IgG-immunoapheresis in highly sensitized renal transplant recipients
16. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients
17. X-linked agammaglobulinemia. A clinical and molecular analysis
18. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study
19. Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes
20. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection
21. Comparison of early IgM-enriched immunoglobulin vs. polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis
22. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases
23. Pregnancy complicated by the antiphospholipid syndrome: Outcomes with intravenous immunoglobulin therapy
24. Treatment of antiphospholipid syndrome in pregnancy
25. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action
26. Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient
27. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation
28. Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease
29. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases
30. Immunomodulatory effect of immunoglobulins
31. Intravenous IgG in Guillain-Barré syndrome
32. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for the therapeutic use (intravenous immunoglobulin, IVIg)
33. Intravenous immune globulin therapy of lupus nephritis: Use of pathogenic anti-DNA-reactive IgG
34. Mechanisms of action of intravenous immune globulin in immune-mediated diseases
35. Southwestern Internal Medicine Conference: High-dose intravenous gamma globulin therapy: How does it work
36. Recommendations for off-label use of intravenously administered immunoglobulin preparations
37. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments
38. High dose intravenous immunoglobulin in systemic lupus erythematosus: Clinical and serological results of a pilot study
39. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis
40. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis
41. High dose intravenous immunoglobulin therapy for myasthenia gravis
42. Randomised trial of plasma exchange, intravenous immunoglobulin and combined treatment in Guillain-Barré syndrome
43. Effect of plasma protein adsorption on protein excretion in kidney transplant recipients with recurrent nephrotic syndrome
44. Neurological complications of intravenous immunoglobulin (IVIg) therapy: An illustrative case of acute encephalopathy following IVIg therapy and a review of the literature
45. IVIG adverse reactions: Potential role of cytokines and vasoactive substances
46. Acute renal failure following immunoglobulin therapy
47. High-dose intravenous IgG treatment and acute renal failure
48. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors
49. High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events
50. Acute renal failure resulting from intravenous immunoglobulin therapy
51. Intravenous immune globulin therapy for neurological diseases
52. Safety and side effects of i.v. immunoglobulin therapy
53. Intravenous immunoglobulin induced nephropathy: A comparison of IVIG therapy
54. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases
55. Klinische Erfahrungen mit IgG-Immunoadsorption bei Patienten mit neurologischen Erkrankungen
56. Local anticoagulation of the extracorporeal circuit with heparin and subsequent neutralization with protamine during immunoadsorption
57. Effects of prophylactic intravenous immunoglobulin-G therapy on humoral and cellular immune components and their functions in burned patients
58. Immunoadsorption in multifocal motor neuropathy
59. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease
60. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA
61. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies